Zota Health Care promoters report no share encumbrance in FY26
Zota Health Care Limited confirmed via a filing to NSE on April 04, 2026, that its promoters and PACs did not pledge any shares during FY26. The declaration, signed by Promoter and Whole-time Director Himanshu Muktilal Zota, covers 39 individuals and entities listed as promoters or promoter group members.

*this image is generated using AI for illustrative purposes only.
Zota Health Care Limited has disclosed that its promoters and Persons Acting in Concert (PAC) did not create any encumbrance on the company's shares during the financial year 2025-26. The declaration confirms that no shares were pledged directly or indirectly other than those already reported previously. This disclosure was submitted to The National Stock Exchange of India Limited on April 04, 2026, under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Himanshu Muktilal Zota, Promoter and Whole-time Director of Zota Health Care Limited , signed the declaration on behalf of the promoters and PAC. The filing stated that none of the individuals or entities in these categories had made any new encumbrances during the specified period. The document was addressed to the Listing Department of the exchange, with copies marked to the Company Secretary and Compliance Officer, as well as the Audit Committee of the Board of Directors.
The disclosure included a comprehensive list of promoters and PAC members attached as Annexure-1. The list categorizes the stakeholders into Promoters and Promoter Group, detailing the names of individuals and entities associated with the company.
Promoter and PAC Details
| Sr No. | Name | Category |
|---|---|---|
| 1 | Manukant Chandulal Zota | Promoter |
| 2 | Himanshubhai Muktilal Zota | Promoter |
| 3 | Ketankumar Chandulal Zota | Promoter |
| 4 | Kamlesh Rajnikant Zota | Promoter |
| 5 | Zota Manukant Chandulal HUF | Promoter Group |
| 6 | Ashokkumar Chandulal Zota (HUF) | Promoter Group |
| 7 | Zota Ketankumar Chandulal | Promoter Group |
| 8 | Himanshu Muktilal Zota HUF | Promoter Group |
| 9 | Anilaben Ketankumar Zota | Promoter Group |
| 10 | Rasilaben Manukantbhai Zota | Promoter Group |
| 11 | Ashokkumar Chandulal Zota | Promoter Group |
| 12 | Varshaben Himanshubhai Zota | Promoter Group |
| 13 | Niralkumar Muktilal Zota | Promoter Group |
| 14 | Induben Muktilal Zota | Promoter Group |
| 15 | Manishaben Kamleshkumar Zota | Promoter Group |
| 16 | Viren Manukant Zota | Promoter Group |
| 17 | Viren Manukant Zota (HUF) | Promoter Group |
| 18 | Heli Ritesh Shah | Promoter Group |
| 19 | Praful Ratilal Vora | Promoter Group |
| 20 | Moxesh Ketanbhai Zota | Promoter Group |
| 21 | Bhikhalal Chhotalal Doshi | Promoter Group |
| 22 | Dhara Mehta | Promoter Group |
| 23 | Chandrikaben Subodhchandra Shah | Promoter Group |
| 24 | Kinjal Nikesh Mehta | Promoter Group |
| 25 | Anjnaben Shrennikumar Gandhi | Promoter Group |
| 26 | Halchandbhai Manilal Mehta | Promoter Group |
| 27 | Manjulaben Pravinbhai Shah | Promoter Group |
| 28 | Kenvi Zota | Promoter Group |
| 29 | Vinodchandra Dhirajlal Mehta | Promoter Group |
| 30 | Sureshkumar Halchandbhai Mehta | Promoter Group |
| 31 | Krinal V Ankhad | Promoter Group |
| 32 | Manisha Tusharkumar Mehta | Promoter Group |
| 33 | Nitaben Rajeshbhai Mehta | Promoter Group |
| 34 | Arunaben Rameshkumar Shah | Promoter Group |
| 35 | Shripal R Mehta | Promoter Group |
| 36 | Kumarpal Rajnikant Mehta | Promoter Group |
| 37 | Nirmalaben A Shah | Promoter Group |
| 38 | Ramila R Mehta | Promoter Group |
| 39 | Dimple Dhaval Shah | Promoter Group |
Historical Stock Returns for Zota Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +6.17% | +12.36% | -5.19% | -20.97% | +30.60% | +625.63% |
Will the absence of new share encumbrances improve Zota Health Care's credit rating or borrowing costs in the upcoming fiscal year?
How might this clean pledge status influence institutional investor confidence and share liquidity in the near term?
Does the lack of new encumbrances suggest the company is generating sufficient internal cash flow to fund expansion?


































